Search

Your search keyword '"Cicero A.F.G."' showing total 283 results
Start Over Author "Cicero A.F.G."
283 results on '"Cicero A.F.G."'

1. Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up

Author

Cicero, A.F.G., primary, Fogacci, F., additional, Rizzoli, E., additional, Giovannini, M., additional, D'Addato, S., additional, Borghi, C., additional, Cicero, A.F.G., additional, Grandi, E., additional, Ventura, F., additional, Coppola, P., additional, Ianniello, E., additional, Soldati, M., additional, Piani, F.M., additional, Iamino, I.R., additional, Palmisano, S., additional, Landolfo, M., additional, and Bacchelli, S., additional

Published
2022
Full Text
View/download PDF

16. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

Author

Pugliese, N.R. Mengozzi, A. Virdis, A. Casiglia, E. Tikhonoff, V. Cicero, A.F.G. Ungar, A. Rivasi, G. Salvetti, M. Barbagallo, C.M. Bombelli, M. Dell’Oro, R. Bruno, B. Lippa, L. D’Elia, L. Verdecchia, P. Mallamaci, F. Cirillo, M. Rattazzi, M. Cirillo, P. Gesualdo, L. Mazza, A. Giannattasio, C. Maloberti, A. Volpe, M. Tocci, G. Georgiopoulos, G. Iaccarino, G. Nazzaro, P. Parati, G. Palatini, P. Galletti, F. Ferri, C. Desideri, G. Viazzi, F. Pontremoli, R. Muiesan, M.L. Grassi, G. Masi, S. Borghi, C. The Working Group on Uric Acid Cardiovascular Risk of the Italian Society of Hypertension

Abstract

Introduction: Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim: We assessed the prognostic role of SUA in patients with and without MS. Methods: We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results: A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previously validated cardiovascular SUA cut-off to predict CVM (> 5.1 mg/dL in women and 5.6 mg/dL in men), elevated SUA levels were significantly associated to a worse outcome in patients with and without MS (all p < 0.0001) and provided a significant net reclassification improvement of 7.1% over the diagnosis of MS for CVM (p = 0.004). Cox regression analyses identified an independent association between SUA and CVM (Hazard Ratio: 1.79 [95% CI, 1.15–2.79]; p < 0.0001) after the adjustment for MS, its single components and renal function. Three specific combinations of the MS components were associated with higher CVM when increasing SUA levels were reported, and systemic hypertension was the only individual component ever-present (all p < 0.0001). Conclusion: Increasing SUA levels are associated with a higher CVM risk irrespective of the presence of MS: a cardiovascular SUA threshold may improve risk stratification. Graphic abstract: [Figure not available: see fulltext.] © 2021, The Author(s).

Published
2021

17. Tracking development assistance for health and for COVID-19: A review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050

Author

Micah, A.E., Cogswell, I.E., Cunningham, B., Ezoe, S., Harle, A.C., Maddison, E.R., McCracken, D., Nomura, S., Simpson, K.E., Stutzman, H.N., Tsakalos, G., Wallace, L.E., Zhao, Y., Zende, R.R., Abbafati, C., Abdelmasseh, M., Abedi, A., Abegaz, K.H., Abhilash, E.S., Abolhassani, H., Abrigo, M.R.M., Adhikari, T.B., Afzal, S., Ahinkorah, B.O., Ahmadi, S., Ahmed, H., Ahmed, M.B., Ahmed Rashid, T., Ajami, M., Aji, B., Akalu, Y., Akunna, C.J., Al Hamad, H., Alam, K., Alanezi, F.M., Alanzi, T.M., Alemayehu, Y., Alhassan, R.K., Alinia, C., Aljunid, S.M., Almustanyir, S.A., Alvis-Guzman, N., Alvis-Zakzuk, N.J., Amini, S., Amini-Rarani, M., Amu, H., Ancuceanu, R., Andrei, C.L., Andrei, T., Angell, B., Anjomshoa, M., Antonio, C.A.T., Antony, C.M., Aqeel, M., Arabloo, J., Arab-Zozani, M., Aripov, T., Arrigo, A., Ashraf, T., Atnafu, D.D., Ausloos, M., Avila-Burgos, L., Awan, A.T., Ayano, G., Ayanore, M.A., Azari, S., Azhar, G.S., Babalola, T.K., Bahrami, M.A., Baig, A.A., Banach, M., Barati, N., Bärnighausen, T.W., Barrow, A., Basu, S., Baune, B.T., Bayati, M., Benzian, H., Berman, A.E., Bhagavathula, A.S., Bhardwaj, N., Bhardwaj, P., Bhaskar, S., Bibi, S., Bijani, A., Bodolica, V., Bragazzi, N.L., Braithwaite, D., Breitborde, N.J.K., Breusov, A.V., Briko, N.I., Busse, R., Cahuana-Hurtado, L., Callander, E.J., Cámera, L.A., Castañeda-Orjuela, C.A., Catalá-López, F., Charan, J., Chatterjee, S., Chattu, S.K., Chattu, V.K., Chen, S., Cicero, A.F.G., Dadras, O., Dahlawi, S.M.A., Dai, X., Dalal, K., Dandona, L., Dandona, R., Davitoiu, D.V., De Neve, J-W, de Sá-Junior, A.R., Denova-Gutiérrez, E., Dhamnetiya, D., Dharmaratne, S.D., Doshmangir, L., Dube, J., Ehsani-Chimeh, E., El Sayed Zaki, M., El Tantawi, M., Eskandarieh, S., Farzadfar, F., Ferede, T.Y., Fischer, F., Foigt, N.A., Freitas, A., Friedman, S.D., Fukumoto, T., Fullman, N., Gaal, P.A., Gad, M.M., Garcia-Gordillo, M.A., Garg, T., Ghafourifard, M., Ghashghaee, A., Gholamian, A., Gholamrezanezhad, A., Ghozali, G., Gilani, S.A., Glăvan, I-R, Glushkova, E.V., Goharinezhad, S., Golechha, M., Goli, S., Guha, A., Gupta, V.B., Gupta, V.K., Haakenstad, A., Haider, M.R., Hailu, A., Hamidi, S., Hanif, A., Harapan, H., Hartono, R.K., Hasaballah, A.I., Hassan, S., Hassanein, M.H., Hayat, K., Hegazy, M.I., Heidari, G., Hendrie, D., Heredia-Pi, I., Herteliu, C., Hezam, K., Holla, R., Hossain, S.., Hosseinzadeh, M., Hostiuc, S., Huda, T.M., Hwang, B-F, Iavicoli, I., Idrisov, B., Ilesanmi, O.S., Irvani, S.S.N., Islam, S.M.S., Ismail, N.E., Isola, G., Jahani, M.A., Jahanmehr, N., Jakovljevic, M., Janodia, M.D., Javaheri, T., Jayapal, S.K., Jayawardena, R., Jazayeri, S.B., Jha, R.P., Jonas, J.B., Joo, T., Joukar, F., Jürisson, M., Kaambwa, B., Kalhor, R., Kanchan, T., Kandel, H., Karami Matin, B., Karimi, S.E., Kassahun, G., Kayode, G.A., Kazemi Karyani, A., Keikavoosi-Arani, L., Khader, Y.S., Khajuria, H., Khalilov, R., Khammarnia, M., Khan, J., Khubchandani, J., Kianipour, N., Kim, G.R., Kim, Y.J., Kisa, A., Kisa, S., Kohler, S., Kosen, S., Koteeswaran, R., Koulmane Laxminarayana, S.L., Koyanagi, A., Krishan, K., Kumar, G.A., Kusuma, D., Lamnisos, D., Lansingh, V.C., Larsson, A.O., Lasrado, S., Le, L.K.D., Lee, S.W.H., Lee, Y.Y., Lim, S.S., Lobo, S.W., Lozano, R., Magdy Abd El Razek, H., Magdy Abd El Razek, M., Mahdavi, M.M., Majeed, A., Makki, A., Maleki, A., Malekzadeh, R., Manda, A.L., Mansour-Ghanaei, F., Mansournia, M.A., Marrugo Arnedo, C.A., Martinez-Valle, A., Masoumi, S.Z., Maude, Ri.J., McKee, M., Medina-Solís, C.E., Menezes, R.G., Meretoja, A., Meretoja, T.J., Mesregah, M.K., Mestrovic, T., Milevska Kostova, N., Miller, T.R., Mini, G.K., Mirica, A., Mirrakhimov, E.M., Mohajer, B., Mohamed, T.A., Mohammadi, M., Mohammadian-Hafshejani, A., Mohammed, S., Moitra, M., Mokdad, A.H., Molokhia, M., Moni, M.A., Moradi, Y., Morze, J., Mousavi, S.M., Mpundu-Kaambwa, C., Muriithi, M.K, Muthupandian, S., Nagarajan, A.J., Naimzada, M.D., Nangia, V., Naqvi, A.A., Narayana, A.I., Nascimento, B.R., Naveed, M., Nayak, B.P., Nazari, J., Ndejjo, R., Negoi, I., Neupane Kandel, S., Nguyen, T.H., Nonvignon, J., Noubiap, J.J., Nwatah, V.E., Oancea, B., Ojelabi, F.A.O., Olagunju, A.T., Olakunde, B.O., Olgiati, S., Olusanya, J.O., Onwujekwe, O.E., Otoiu, A., Otstavnov, N., Otstavnov, S.S., Owolabi, M.O., Padubidri, J.R., Palladino, R., Panda-Jonas, S., Park, E-C, Pashazadeh Kan, F., Pawar, S., Pazoki Toroudi, H., Pereira, D.M., Perianayagam, A., Pesudovs, K., Piccinelli, C., Postma, M.J., Prada, S.I., Rabiee, M., Rabiee, N., Rahim, F., Rahimi-Movaghar, V., Rahman, M.H.U., Rahman, M., Rahmani, A.M., Ram, U., Ranabhat, C.L., Ranasinghe, P., Rao, C.R., Rathi, P., Rawaf, D.L., Rawaf, S., Rawal, L., Rawassizadeh, R., Reiner Jr, R.C., Renzaho, A.M.N., Reshmi, B., Riaz, M.A., Ripon, R.K., Saad, A.M., Sahraian, M.A., Sahu, M., Salama, J.S., Salehi, S., Samy, A.M., Sanabria, J., Sanmarchi, F., Santos, J.V., Santric-Milicevic, M.M., Sathian, B., Savic, M., Saxena, D., Sayyah, M., Schwendicke, F., Senthilkumaran, S., Sepanlou, S.G., Seylani, A., Shahabi, S., Shaikh, M.A., Sheikh, A., Shetty, A., Shetty, P.H., Shibuya, K., Shrime, M.G., Shuja, K.H., Singh, J.A., Skryabin, V.Y., Skryabina, A.A., Soltani, S., Soofi, M., Spurlock, E.E., Stefan, S.C., Szerencsés, V., Szócska, M., Tabarés-Seisdedos, R., Taddele, B.W., Tefera, Y.G., Thavamani, A., Tobe-Gai, R., Topor-Madry, R., Tovani-Palone, M.R., Tran, B.X., Tudor Car, L., Ullah, A., Ullah, S., Umar, N., Undurraga, E.A., Valdez, P.R., Vasankari, T.J., Villafañe, J.H., Violante, F.S., Vlassov, V., Vo, B., Vollmer, S., Vos, T., Vu, G.T., Vu, L.G., Wamai, R.G., Werdecker, A., Woldekidan, M.A., Wubishet, B.L., Xu, G., Yaya, S., Yazdi-Feyzabadi, V., Yiğit, V., Yip, P., Yirdaw, B.W., Yonemoto, N., Younis, M.Z., Yu, C., Yunusa, I., Zahirian Moghadam, T., Zandian, H., Zastrozhin, M.S., Zastrozhina, A., Zhang, Z-J, Ziapour, A., Zuniga, Y.M.H., Hay, S.I., Murray, C. J.L., Dieleman, J.L., Micah, A.E., Cogswell, I.E., Cunningham, B., Ezoe, S., Harle, A.C., Maddison, E.R., McCracken, D., Nomura, S., Simpson, K.E., Stutzman, H.N., Tsakalos, G., Wallace, L.E., Zhao, Y., Zende, R.R., Abbafati, C., Abdelmasseh, M., Abedi, A., Abegaz, K.H., Abhilash, E.S., Abolhassani, H., Abrigo, M.R.M., Adhikari, T.B., Afzal, S., Ahinkorah, B.O., Ahmadi, S., Ahmed, H., Ahmed, M.B., Ahmed Rashid, T., Ajami, M., Aji, B., Akalu, Y., Akunna, C.J., Al Hamad, H., Alam, K., Alanezi, F.M., Alanzi, T.M., Alemayehu, Y., Alhassan, R.K., Alinia, C., Aljunid, S.M., Almustanyir, S.A., Alvis-Guzman, N., Alvis-Zakzuk, N.J., Amini, S., Amini-Rarani, M., Amu, H., Ancuceanu, R., Andrei, C.L., Andrei, T., Angell, B., Anjomshoa, M., Antonio, C.A.T., Antony, C.M., Aqeel, M., Arabloo, J., Arab-Zozani, M., Aripov, T., Arrigo, A., Ashraf, T., Atnafu, D.D., Ausloos, M., Avila-Burgos, L., Awan, A.T., Ayano, G., Ayanore, M.A., Azari, S., Azhar, G.S., Babalola, T.K., Bahrami, M.A., Baig, A.A., Banach, M., Barati, N., Bärnighausen, T.W., Barrow, A., Basu, S., Baune, B.T., Bayati, M., Benzian, H., Berman, A.E., Bhagavathula, A.S., Bhardwaj, N., Bhardwaj, P., Bhaskar, S., Bibi, S., Bijani, A., Bodolica, V., Bragazzi, N.L., Braithwaite, D., Breitborde, N.J.K., Breusov, A.V., Briko, N.I., Busse, R., Cahuana-Hurtado, L., Callander, E.J., Cámera, L.A., Castañeda-Orjuela, C.A., Catalá-López, F., Charan, J., Chatterjee, S., Chattu, S.K., Chattu, V.K., Chen, S., Cicero, A.F.G., Dadras, O., Dahlawi, S.M.A., Dai, X., Dalal, K., Dandona, L., Dandona, R., Davitoiu, D.V., De Neve, J-W, de Sá-Junior, A.R., Denova-Gutiérrez, E., Dhamnetiya, D., Dharmaratne, S.D., Doshmangir, L., Dube, J., Ehsani-Chimeh, E., El Sayed Zaki, M., El Tantawi, M., Eskandarieh, S., Farzadfar, F., Ferede, T.Y., Fischer, F., Foigt, N.A., Freitas, A., Friedman, S.D., Fukumoto, T., Fullman, N., Gaal, P.A., Gad, M.M., Garcia-Gordillo, M.A., Garg, T., Ghafourifard, M., Ghashghaee, A., Gholamian, A., Gholamrezanezhad, A., Ghozali, G., Gilani, S.A., Glăvan, I-R, Glushkova, E.V., Goharinezhad, S., Golechha, M., Goli, S., Guha, A., Gupta, V.B., Gupta, V.K., Haakenstad, A., Haider, M.R., Hailu, A., Hamidi, S., Hanif, A., Harapan, H., Hartono, R.K., Hasaballah, A.I., Hassan, S., Hassanein, M.H., Hayat, K., Hegazy, M.I., Heidari, G., Hendrie, D., Heredia-Pi, I., Herteliu, C., Hezam, K., Holla, R., Hossain, S.., Hosseinzadeh, M., Hostiuc, S., Huda, T.M., Hwang, B-F, Iavicoli, I., Idrisov, B., Ilesanmi, O.S., Irvani, S.S.N., Islam, S.M.S., Ismail, N.E., Isola, G., Jahani, M.A., Jahanmehr, N., Jakovljevic, M., Janodia, M.D., Javaheri, T., Jayapal, S.K., Jayawardena, R., Jazayeri, S.B., Jha, R.P., Jonas, J.B., Joo, T., Joukar, F., Jürisson, M., Kaambwa, B., Kalhor, R., Kanchan, T., Kandel, H., Karami Matin, B., Karimi, S.E., Kassahun, G., Kayode, G.A., Kazemi Karyani, A., Keikavoosi-Arani, L., Khader, Y.S., Khajuria, H., Khalilov, R., Khammarnia, M., Khan, J., Khubchandani, J., Kianipour, N., Kim, G.R., Kim, Y.J., Kisa, A., Kisa, S., Kohler, S., Kosen, S., Koteeswaran, R., Koulmane Laxminarayana, S.L., Koyanagi, A., Krishan, K., Kumar, G.A., Kusuma, D., Lamnisos, D., Lansingh, V.C., Larsson, A.O., Lasrado, S., Le, L.K.D., Lee, S.W.H., Lee, Y.Y., Lim, S.S., Lobo, S.W., Lozano, R., Magdy Abd El Razek, H., Magdy Abd El Razek, M., Mahdavi, M.M., Majeed, A., Makki, A., Maleki, A., Malekzadeh, R., Manda, A.L., Mansour-Ghanaei, F., Mansournia, M.A., Marrugo Arnedo, C.A., Martinez-Valle, A., Masoumi, S.Z., Maude, Ri.J., McKee, M., Medina-Solís, C.E., Menezes, R.G., Meretoja, A., Meretoja, T.J., Mesregah, M.K., Mestrovic, T., Milevska Kostova, N., Miller, T.R., Mini, G.K., Mirica, A., Mirrakhimov, E.M., Mohajer, B., Mohamed, T.A., Mohammadi, M., Mohammadian-Hafshejani, A., Mohammed, S., Moitra, M., Mokdad, A.H., Molokhia, M., Moni, M.A., Moradi, Y., Morze, J., Mousavi, S.M., Mpundu-Kaambwa, C., Muriithi, M.K, Muthupandian, S., Nagarajan, A.J., Naimzada, M.D., Nangia, V., Naqvi, A.A., Narayana, A.I., Nascimento, B.R., Naveed, M., Nayak, B.P., Nazari, J., Ndejjo, R., Negoi, I., Neupane Kandel, S., Nguyen, T.H., Nonvignon, J., Noubiap, J.J., Nwatah, V.E., Oancea, B., Ojelabi, F.A.O., Olagunju, A.T., Olakunde, B.O., Olgiati, S., Olusanya, J.O., Onwujekwe, O.E., Otoiu, A., Otstavnov, N., Otstavnov, S.S., Owolabi, M.O., Padubidri, J.R., Palladino, R., Panda-Jonas, S., Park, E-C, Pashazadeh Kan, F., Pawar, S., Pazoki Toroudi, H., Pereira, D.M., Perianayagam, A., Pesudovs, K., Piccinelli, C., Postma, M.J., Prada, S.I., Rabiee, M., Rabiee, N., Rahim, F., Rahimi-Movaghar, V., Rahman, M.H.U., Rahman, M., Rahmani, A.M., Ram, U., Ranabhat, C.L., Ranasinghe, P., Rao, C.R., Rathi, P., Rawaf, D.L., Rawaf, S., Rawal, L., Rawassizadeh, R., Reiner Jr, R.C., Renzaho, A.M.N., Reshmi, B., Riaz, M.A., Ripon, R.K., Saad, A.M., Sahraian, M.A., Sahu, M., Salama, J.S., Salehi, S., Samy, A.M., Sanabria, J., Sanmarchi, F., Santos, J.V., Santric-Milicevic, M.M., Sathian, B., Savic, M., Saxena, D., Sayyah, M., Schwendicke, F., Senthilkumaran, S., Sepanlou, S.G., Seylani, A., Shahabi, S., Shaikh, M.A., Sheikh, A., Shetty, A., Shetty, P.H., Shibuya, K., Shrime, M.G., Shuja, K.H., Singh, J.A., Skryabin, V.Y., Skryabina, A.A., Soltani, S., Soofi, M., Spurlock, E.E., Stefan, S.C., Szerencsés, V., Szócska, M., Tabarés-Seisdedos, R., Taddele, B.W., Tefera, Y.G., Thavamani, A., Tobe-Gai, R., Topor-Madry, R., Tovani-Palone, M.R., Tran, B.X., Tudor Car, L., Ullah, A., Ullah, S., Umar, N., Undurraga, E.A., Valdez, P.R., Vasankari, T.J., Villafañe, J.H., Violante, F.S., Vlassov, V., Vo, B., Vollmer, S., Vos, T., Vu, G.T., Vu, L.G., Wamai, R.G., Werdecker, A., Woldekidan, M.A., Wubishet, B.L., Xu, G., Yaya, S., Yazdi-Feyzabadi, V., Yiğit, V., Yip, P., Yirdaw, B.W., Yonemoto, N., Younis, M.Z., Yu, C., Yunusa, I., Zahirian Moghadam, T., Zandian, H., Zastrozhin, M.S., Zastrozhina, A., Zhang, Z-J, Ziapour, A., Zuniga, Y.M.H., Hay, S.I., Murray, C. J.L., and Dieleman, J.L.

Abstract

Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached $8·8 trillion (95% uncertainty interval [UI] 8·7–8·8) or $1132 (1119–1143) per person. Spending on health varied within and across income groups and geographical regions. Of this tota

Published
2021

19. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality over 20 Years

Author

Virdis, A. Masi, S. Casiglia, E. Tikhonoff, V. Cicero, A.F.G. Ungar, A. Rivasi, G. Salvetti, M. Barbagallo, C.M. Bombelli, M. Dell'Oro, R. Bruno, B. Lippa, L. D'Elia, L. Verdecchia, P. Mallamaci, F. Cirillo, M. Rattazzi, M. Cirillo, P. Gesualdo, L. Mazza, A. Giannattasio, C. Maloberti, A. Volpe, M. Tocci, G. Georgiopoulos, G. Iaccarino, G. Nazzaro, P. Parati, G. Palatini, P. Galletti, F. Ferri, C. Desideri, G. Viazzi, F. Pontremoli, R. Muiesan, M.L. Grassi, G. Borghi, C.

Abstract

Serum uric acid (SUA) levels discriminating across the different strata of cardiovascular risk is still unknown. By utilizing a large population-based database, we assessed the threshold of SUA that increases the risk of total mortality and cardiovascular mortality (CVM). The URRAH study (Uric Acid Right for Heart Health) is a multicentre retrospective, observational study, which collected data from several large population-based longitudinal studies in Italy and subjects recruited in the hypertension clinics of the Italian Society of Hypertension. Total mortality was defined as mortality for any cause, CVM as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. A total of 22 714 subjects were included in the analysis. Multivariate Cox regression analyses identified an independent association between SUA and total mortality (hazard ratio, 1.53 [95% CI, 1.21-1.93]) or CVM (hazard ratio, 2.08 [95% CI, 1.146-2.97]; P

Published
2020

20. Nutraceuticals and blood pressure control: A European Society of Hypertension position document

Author

Borghi, C., Prof. Tsioufis, K. Agabiti-Rosei, E. Burnier, M. Cicero, A.F.G. Clement, D. Coca, A. Desideri, G. Grassi, G. Lovic, D. Lurbe, E. Kahan, T. Kreutz, R. Jelakovic, B. Polonia, J. Redon, J. Van De Borne, P. Mancia, G.

Abstract

High-normal blood pressure (BP) is associated with an increased risk of cardiovascular disease, however the cost-benefit ratio of the use of antihypertensive treatment in these patients is not yet clear. Some dietary components and natural products seems to be able to significantly lower BP without significant side effects. The aim of this position document is to highlight which of these products have the most clinically significant antihypertensive action and wheter they could be suggested to patients with high-normal BP. Among foods, beetroot juice has the most covincing evidence of antihypertensive effect. Antioxidant-rich beverages (teas, coffee) could be considered. Among nutrients, magnesium, potassium and vitamin C supplements could improve BP. Among nonnutrient-nutraceuticals, soy isoflavones could be suggested in perimenopausal women, resveratrol in insulin-resistant patients, melatonin in study participants with night hypertension. In any case, the nutracutical approach has never to substitute the drug treatment, when needed. © 2020 Lippincott Williams and Wilkins. All rights reserved.

Published
2020

23. The realization of a project aimed at reducing the plasmatic lipid level in a large Italian population improves the mean calcium daily intake: the Brisighella Study

Author

Gaddi, A., Cicero, A.F.G., Wani, F.O. Odo, Dormi, A., Pasquarelli, V., and D'Addato, S.

Abstract

Objectives: Evaluation of the impact of a coronary heart disease prevention program on calcium, magnesium, phosphorus and vitamin D dietary intake in respect of recommended daily allowances in a large Italian rural population. Design: Retrospective analysis of the Brisighella Study dietary data. The Brisighella Study started in 1972 as a longitudinal study on atherosclerosis risk factors. Setting: Brisighella, a rural North Italian village. Subjects: The Brisighella population&apos;s dietary habits were monitored from 1980 every 4 h through a dietary record sheet. 1350 constantly tested subjects were subdivided according to NHI Consensus Conference on Calcium RDA. Intervention: In 1986, the studied subjects were invited to reduce their consumption of animal fats and cholesterol through a Nutrition Educational Program (NEP). Results: Before NEP, calcium intake was low in each sex and age category: 20-40% of the populatioin had a daily intake < 550mg. In 1988, among the 1350 subjects who constantly completed the questionnaire (M=651, F = 699), the mean calcium intake significantly rose in all age categories: M = 1003 (25-65 y) and 877 (> 65) mg/24 h (P < 0.001 vs 1984); F = 923 (25-50), 860 (51-65) and 767 (> 65) mg/24 h (P < 0.05). In 1992, 3 y after the NEP conclusion, calcium intake dropped in each sex and age category. The NEP influenced vitamin D, phosphorus and magnesium intakes less. Conclusions: A collective NEP aimed at lowering saturated fats and cholesterol intakes, improves the calcium intake; in order to maintain their efficacy on nutritional habit changes, these programs must become an ongoing item. Descriptors: calcium; magnesium; vitamin D; epidemiology; nutritional programs; coronary heart disease; prevention project, Introduction Bone is the mineral storage tank of the human body: it contains 99% of all body calcium in hydroxyapatite crystals, 85% of body phosphorus and 65% of body magnesium. [...]

Published
2001

24. Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study

Author

Cicero, Arrigo F.G., primary, Fogacci, Federica, additional, Tocci, Giuliano, additional, Ventura, Fulvio, additional, Presta, Vivianne, additional, Grandi, Elisa, additional, Rizzoli, Elisabetta, additional, D'Addato, Sergio, additional, Borghi, Claudio, additional, Cicero, A.F.G., additional, D'Addato, S., additional, Grandi, E., additional, Fogacci, F., additional, Giovannini, M., additional, Rizzoli, E., additional, Ventura, F., additional, Coppola, P., additional, Piani, F.M., additional, Soldati, M., additional, Iamino, I.R., additional, Palmisano, S., additional, Landolfo, M., additional, Rosticci, M., additional, Derosa, G., additional, Bacchelli, S., additional, and Borghi, C., additional

Published
2020
Full Text
View/download PDF

26. The Role of Nutraceuticals in Statin Intolerant Patients

Author

Banach, M. Patti, A.M. Giglio, R.V. Cicero, A.F.G. Atanasov, A.G. Bajraktari, G. Bruckert, E. Descamps, O. Djuric, D.M. Ezhov, M. Fras, Z. von Haehling, S. Katsiki, N. Langlois, M. Latkovskis, G. Mancini, G.B.J. Mikhailidis, D.P. Mitchenko, O. Moriarty, P.M. Muntner, P. Nikolic, D. Panagiotakos, D.B. Paragh, G. Paulweber, B. Pella, D. Pitsavos, C. Reiner, Ž. Rosano, G.M.C. Rosenson, R.S. Rysz, J. Sahebkar, A. Serban, M.-C. Vinereanu, D. Vrablík, M. Watts, G.F. Wong, N.D. Rizzo, M. International Lipid Expert Panel (ILEP)

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction. © 2018 American College of Cardiology Foundation

Published
2018

31. Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel

Author

Cicero, A.F.G. Colletti, A. Bajraktari, G. Descamps, O. Djuric, D.M. Ezhov, M. Fras, Z. Katsiki, N. Langlois, M. Latkovskis, G. Panagiotakos, D.B. Paragh, G. Mikhailidis, D.P. Mitchenko, O. Paulweber, B. Pella, D. Pitsavos, C. Reiner, Z. Ray, K.K. Rizzo, M. Sahebkar, A. Serban, M.-C. Sperling, L.S. Toth, P.P. Vinereanu, D. Vrablík, M. Wong, N.D. Banach, M. on behalf of the International Lipid Expert Panel (ILEP)

Abstract

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipidlowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting. © The Author(s) 2017. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved.

Published
2017

37. Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin

Author

Caliceti, C., primary, Rizzo, P., additional, Ferrari, R., additional, Fortini, F., additional, Aquila, G., additional, Leoncini, E., additional, Zambonin, L., additional, Rizzo, B., additional, Calabria, D., additional, Simoni, P., additional, Mirasoli, M., additional, Guardigli, M., additional, Hrelia, S., additional, Roda, A., additional, and Cicero, A.F.G., additional

Published
2017
Full Text
View/download PDF

41. [OP.1B.02] SERUM URIC ACID AND BLOOD PRESSURE IN EUROPEAN RURAL POPULATION WITH NORMAL KIDNEY FUNCTION. DATA FROM BRISGHELLA HEART STUDY (ITALY) AND ENAH STUDY (CROATIA)

Author

Karanovic, S., primary, Ivkovic, V., additional, Parini, A., additional, Vrdoljak, A., additional, Abramovic-Baric, M., additional, Bacchelli, S., additional, Cagnati, M., additional, Francesco, A., additional, Cicero, A.F.G., additional, D’Addato, S., additional, Esposti, D. Degli, additional, Fucek, M., additional, Grandi, E., additional, Kos, J., additional, Laganovic, M., additional, Rosticci, M., additional, Rogic, D., additional, Vukovic, I., additional, Borghi, C., additional, and Jelakovic, B., additional

Published
2016
Full Text
View/download PDF

42. [PP.19.10] ISOLATED SYSTOLIC HYPERTENSION CHARACTERISTICS

Author

Parini, A., primary, Ivkovic, V., additional, Vrdoljak, A., additional, Baric, M. Abramovic, additional, Bacchelli, S., additional, Cagnati, M., additional, Cicero, A.F.G., additional, Addato, S.D., additional, Esposti, D. degli, additional, Fucek, M., additional, Grandi, E., additional, Ivandic, E., additional, Karanovic, S., additional, Laganovic, M., additional, Pecin, I., additional, Rosticci, M., additional, Rogic, D., additional, Jelakovic, B., additional, and Borghi, C., additional

Published
2016
Full Text
View/download PDF

43. [PP.03.11] PREHYPERTENSION IS ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN EUROPEAN RURAL POPULATION- DATA FROM BRISGHELA HEART STUDY (ITALY) AND ENAH STUDY (CROATIA)

Author

Parini, A., primary, Ivkovic, V., additional, Vrdoljak, A., additional, Baric, M. Abramovic, additional, Bacchelli, S., additional, Cagnati, M., additional, Cicero, A.F.G., additional, D’Addato, S., additional, Esposti, D. degli, additional, Fucek, M., additional, Grandi, D., additional, Ivandic, E., additional, Karanovic, S., additional, Kos, J., additional, Laganovic, M., additional, Rosticci, M., additional, Rogic, D., additional, Jelakovic, B., additional, and Borghi, C., additional

Published
2016
Full Text
View/download PDF

49. [PP.19.05] PREHYPERTENSION IN EUROPEAN RURAL POPULATION - DATA FROM THE BRISGHELLA HEART STUDY (ITALY) AND ENAH STUDY (CROATIA)

Author

IVKOVIC, V., primary, Parini, A., additional, Vrdoljak, A., additional, Karanovic, S., additional, Baric, M. Abramovic, additional, Bacchelli, S., additional, Cagnati, M., additional, Cicero, A.F.G., additional, D’Addato, S., additional, Esposti, D. degli, additional, Fucek, M., additional, Grandi, E., additional, Kos, J., additional, Laganovic, M., additional, Rosticci, M., additional, Rogic, D., additional, Vukovic, I., additional, Borghi, C., additional, and Jelakovic, B., additional

Published
2016
Full Text
View/download PDF

50. [OP.7B.06] METABOLIC SYNDROME IN EUROPEAN RURAL POPULATION- DATA FROM THE BRISGHELLA HEART STUDY (ITALY) AND ENAH STUDY (CROATIA)

Author

Parini, A., primary, Ivkovic, V., additional, Vrdoljak, A., additional, Baric, M. Abramovic, additional, Bacchelli, S., additional, Cagnati, M., additional, Cicero, A.F.G., additional, D’addato, S., additional, Esposti, D. Degli, additional, Fucek, M., additional, Grandi, E., additional, Ivandic, E., additional, Karanovic, S., additional, Laganovic, M., additional, Pecin, I., additional, Rosticci, M., additional, Rogic, D., additional, Jelakovic, B., additional, and Borghi, C., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results